Wegovy HD vs Zepbound: Head-to-Head Weight Loss Comparison
For the first time, semaglutide matches tirzepatide in weight loss efficacy. Here's how Wegovy HD stacks up against Zepbound on every metric that matters.
Wegovy HD: Semaglutide 7.2mg — 20.7% weight loss (STEP UP)
Zepbound: Tirzepatide 15mg — 20.9% weight loss (SURMOUNT-1)
The gap: Virtually eliminated at these doses
The Numbers Side by Side
| Metric | Wegovy HD (7.2mg) | Zepbound (15mg) |
|---|---|---|
| Mean weight loss | 20.7% | 20.9% |
| ≥20% weight loss | ~50% | ~57% |
| ≥25% weight loss | ~33% | ~36% |
| Mechanism | GLP-1 single agonist | GLP-1/GIP dual agonist |
| Dosing | Once weekly | Once weekly |
| Cardiovascular data | Yes (SELECT trial) | Pending (SURPASS-CVOT) |
| Available as pill | Yes (oral Wegovy 25mg) | No (orforglipron pending) |
| Self-pay cost | TBD (HD), $349+ (standard) | $550+ |
Where Wegovy HD Wins
- Cardiovascular proof: SELECT trial demonstrated 20% reduction in major cardiac events. Zepbound's CV outcomes trial is still running.
- Oral option exists: If you can't tolerate injection-level doses, oral Wegovy 25mg delivers 16.6% weight loss at $149/month. No oral tirzepatide equivalent yet.
- Broader safety database: Semaglutide has been on-market since 2017 (Ozempic), giving it the longest real-world safety record.
Where Zepbound Wins
- Slightly higher efficacy ceiling: At the top dose, tirzepatide edges out semaglutide by a small margin.
- Dual mechanism: GLP-1 + GIP agonism may provide additional metabolic benefits.
- Sleep apnea indication: Zepbound is FDA-approved for moderate-to-severe OSA.
Embody · $149 first mo
Compare Semaglutide Providers →Compounded medications are not FDA-approved. Paid link
Compounded Alternatives at Lower Cost
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
from $147/mo
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
The Bottom Line
The efficacy gap between semaglutide and tirzepatide has essentially closed at their highest approved doses. The decision now comes down to cardiovascular data (advantage: Wegovy), cost (advantage: semaglutide ecosystem), additional indications (advantage: Zepbound for sleep apnea), and oral availability (advantage: Wegovy pill). Both are excellent medications.
Sources
- STEP UP trial, semaglutide 7.2mg, 2026
- SURMOUNT-1 trial, tirzepatide 15mg, 2022
- SURMOUNT-5 head-to-head trial, 2024
- SELECT cardiovascular outcomes trial, NEJM 2023